scholarly journals mu-Opioid Receptor Polymorphisms and Breast Cancer Recurrence in Adult Korean Women Undergoing Breast Cancer Surgery: A Retrospective Study

2020 ◽  
Vol 17 (18) ◽  
pp. 2941-2946
Author(s):  
Yea-Ji Lee ◽  
Chung-Sik Oh ◽  
Ji Min Choi ◽  
Sangtae Park ◽  
Seong-Hyop Kim
2016 ◽  
Vol 19 (2) ◽  
pp. 206 ◽  
Author(s):  
Chung-Sik Oh ◽  
Seung-Hyun Lee ◽  
Young-Bum Yoo ◽  
Jung-Hyun Yang ◽  
Seong-Hyop Kim

2021 ◽  
Author(s):  
Yasuaki Uemoto ◽  
Megumi Uchida ◽  
Naoto Kondo ◽  
Yumi Wanifuchi-Endo ◽  
Takashi Fujita ◽  
...  

Abstract Purpose: Although chronic postsurgical pain (CPSP) after breast cancer surgery is a common and prevalent postsurgical adverse event, the need for CPSP treatment has not been investigated. This study examined the proportion of patients who needed treatment for CPSP and associated predictors. Methods: We conducted a cross-sectional study with female patients who underwent breast cancer surgery at our institution. Participants were aged ≤65 years at the time of this study and were at least 1 year post surgery. The questionnaire examined the presence of and need for treatment for CPSP and included the Japanese version of the Concerns about Recurrence Scale (CARS-J). Multivariate analyses were used to identify independent predictors of needing treatment for CPSP.Results: In total, 305 patients completed the questionnaire. The mean time since surgery was 67.1 months; 151 (51%) patients developed CPSP after breast cancer surgery and 61 (39%) needed treatment for CPSP. Among patients that developed CPSP, the fear of breast cancer recurrence as assessed by the CARS-J (odds ratio [OR] 2.22, 95% confidence interval [CI]: 1.30–3.81, P=0.004) and >2 postsurgical pain regions (OR 2.52, 95% CI: 1.16–5.57, P=0.020) were independent predictors of needing treatment for CPSP.Conclusions: This study is the first to identify the proportion and predictors of patients who need treatment for CPSP. Fear of breast cancer recurrence and >2 postsurgical pain regions may predict the need for CPSP treatment among patients following breast cancer surgery.


2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Fumimasa Amaya ◽  
Toyoshi Hosokawa ◽  
Akiko Okamoto ◽  
Megumi Matsuda ◽  
Yosuke Yamaguchi ◽  
...  

Regional analgesia, opioids, and several oral analgesics are commonly used for the treatment of acute pain after breast cancer surgery. While all of these treatments can suppress the acute postsurgical pain, there is growing evidence that suggests that the postsurgical comorbidity will differ in accordance with the type of analgesic used during the surgery. Our current study reviewed the effect of analgesics used for acute pain treatments on the major comorbidities that occur after breast cancer surgery. A considerable number of clinical studies have been performed to investigate the relationship between the acute analgesic regimen and common comorbidities, including inadequate quality of recovery after the surgery, persistent postsurgical pain, and cancer recurrence. Previous studies have shown that the choice of the analgesic modality does affect the postsurgical comorbidity. In general, the use of regional analgesics has a beneficial effect on the occurrence of comorbidity. In order to determine the best analgesic choice after breast cancer surgery, prospective studies that are based on a clear definition of the comorbidity state will need to be undertaken in the future.


SpringerPlus ◽  
2015 ◽  
Vol 4 (1) ◽  
Author(s):  
Kassandra Ferreira Pessoa Fukushima ◽  
Luana Aroucha Carmo ◽  
Adriana Carvalho Borinelli ◽  
Caroline Wanderley Souto Ferreira

2019 ◽  
Vol 130 (1) ◽  
pp. 31-40 ◽  
Author(s):  
Seokha Yoo ◽  
Han-Byoel Lee ◽  
Wonshik Han ◽  
Dong-Young Noh ◽  
Sun-Kyung Park ◽  
...  

Abstract EDITOR’S PERSPECTIVE What We Know about This Topic IV anesthesia may impair anticancer immunity less than volatile anesthesia and therefore reduce recurrence risk What This Article Tells Us That Is New In a large propensity-matched retrospective cohort analysis, the authors compared total IV and volatile anesthesia for breast cancer surgery Recurrence hazard was similar with each approach Selection of IV or volatile anesthesia should be based on factors other than cancer recurrence Background The association between type of anesthesia used and recurrence of cancer remains controversial. This retrospective cohort study compared the influence of total IV anesthesia and inhalation anesthesia on the primary outcome of recurrence-free survival after breast cancer surgery. Methods The authors reviewed the electronic medical records of patients who had breast cancer surgery at a tertiary care teaching hospital between January 2005 and December 2013. The patients were grouped according to whether IV or inhalation anesthesia was used for surgery. Propensity score matching was used to account for differences in baseline characteristics. Kaplan–Meier survival curves were constructed to evaluate the influence of type of anesthesia on recurrence-free survival and overall survival. The risks of cancer recurrence and all-cause mortality were compared between each type of anesthesia. Results Of 7,678 patients who had breast cancer surgery during the study period, data for 5,331 patients were available for analysis (IV group, n = 3,085; inhalation group, n = 2,246). After propensity score matching, 1,766 patients remained in each group. Kaplan–Meier survival curves showed that there was no significant difference in recurrence-free survival or overall survival between the two groups, with 5-yr recurrence-free survival rates of 93.2% (95% CI, 91.9 to 94.5) in the IV group and 93.8% (95% CI, 92.6 to 95.1) in the inhalation group. Inhalation anesthesia had no significant impact on recurrence-free survival (hazard ratio, 0.96; 95% CI, 0.69 to 1.32; P = 0.782) or overall survival (hazard ratio, 0.96; 95% CI, 0.69 to 1.33, P = 0.805) when compared with total IV anesthesia. Conclusions The authors found no association between type of anesthesia used and the long-term prognosis of breast cancer. The results of this retrospective cohort study do not suggest specific selection of IV or inhalation anesthesia for breast cancer surgery.


Oncology ◽  
2000 ◽  
Vol 58 (3) ◽  
pp. 185-190 ◽  
Author(s):  
X. Pivot ◽  
L. Asmar ◽  
G.N. Hortobagyi ◽  
R. Theriault ◽  
F. Pastorini ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document